Regulatory

AbbVie receives EC approval for Aquipta to treat migraine

Pharmaceutical Technology

AbbVie has received approval from the EC for Aquipta, an oral CGRP receptor antagonist, for the acute treatment of migraine in adults, with or without aura.

Pain & Anaesthesia

Read full story

pharminent June 3, 2026 (Last updated: June 3, 2026)

Pharmaceutical Technology

AbbVie has received approval from the EC for Aquipta, an oral CGRP receptor antagonist, for the acute treatment of migraine in adults, with or without aura.

Pain & Anaesthesia

Read full story

Related Stories

Replimune gets early August decision date for twice-rejected melanoma drug

Ionis secures market expansion for Tryngolza as FDA clears severe hypertriglyceridemia use

MSD’s Keytruda-Padcev combo secures EC approval for MIBC

You May Have Missed

Lilly Medicare GLP-1 Bridge Launches July 1 With Foundayo and Zepbound

Moderna Maps R&D ‘Horizons’ as 2028 Break-Even Goal Looms

Replimune gets early August decision date for twice-rejected melanoma drug

Moderna looks out to R&D ‘horizons’ as 2028 break-even goal looms